A recent meta-analysis of clinical trials that compared patients who took varenicline to patients who took a placebo found that those who took the drug had a slightly higher chance of developing cardiovascular events. Although the increased risk was not statistically significant, the drug’s package insert has been updated to include this information. Prior to initiating therapy, the drug’s risk and benefits should be weighed since smoking is a major risk factor for cardiovascular disease. How often do you counsel patients about therapies for smoking cessation?
For more information, please see the article in FDA.
“Image courtesy of [digitalart]/ FreeDigitalPhotos.net“